ArticleCureus2025
Real-World Comparative Effectiveness of Ferric Derisomaltose Versus Conventional Iron Treatment in Postpartum Hemorrhage-Related Anemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostpartum hemorrhage (PPH) can lead to acute iron deficiency anemia, negatively affecting maternal health and infant care by contributing to fatigue, depression, and difficulties with breastfeeding. There is a clinical need for rapid and effective iron supplementation.
objectiveThis study aimed to evaluate the real-world effectiveness of ferric derisomaltose (FDI), which allows for single high-dose intravenous administration, in comparison with conventional treatment combining intravenous and oral iron administration.
methodsThis retrospective observational study included postpartum women with hemoglobin (Hb) levels <8 g/dL within three days after delivery between April 2023 and April 2025. Patients in the FDI group received a single 1000 mg intravenous dose of FDI, while the conventional treatment group received intravenous saccharated ferric oxide and oral sodium ferrous citrate. Hematologic parameters (Hb, serum iron, total iron-binding capacity, ferritin, reticulocyte count, and serum phosphate) were evaluated at two weeks and one month postpartum.
resultsA total of 91 patients met the inclusion criteria (38 in the conventional treatment group and 53 in the FDI group). Hb levels were significantly higher and anemia rates significantly lower in the FDI group at both two weeks and one month postpartum. Serum iron and ferritin levels were also significantly higher in the FDI group. No cases of hypophosphatemia were observed in either group.
conclusionSingle-dose intravenous FDI demonstrated earlier and more effective correction of postpartum anemia compared with conventional treatment, with a favorable safety profile. FDI may represent a strong treatment option in real-world clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.